Key facts
- It has raised $10.6M.
- Notable investors include Creative Destruction Lab, MedTech Innovator, University of Toronto, Keiretsu Forum, Sony Innovation Fund — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Sinaptica Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sinaptica Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sinaptica Therapeutics
Operator of a non-invasive personalized neuromodulation platform intended to support the treatment of Alzheimer's. The company offers technology that induces neuroplasticity, strengthens the brain's key memory network and is protected by broad patents, enabling individuals affected by Alzheimer's, through personalized therapeutic support, to experience a measurable slowing of disease progression.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 16
- Website
- sinapticatx.com/
- Ownership
- Privately Held (backing)
Sinaptica Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sinaptica Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sinaptica Therapeutics in its N-PORT filings yet. We sweep new filings monthly.